Biogen has entered into an agreement with Vanqua Bio to acquire global rights to an experimental oral therapy for immune-related disorders, in a deal valued at up to USD 1.06 billion.

Under the terms, Vanqua Bio will receive an upfront payment of USD 70 million and could earn as much as USD 990 million in additional milestone payments tied to development, regulatory, and commercial achievements.

The potential therapy, which is currently in the preclinical stage, targets a protein linked to several inflammatory and autoimmune conditions. Biogen will assume full responsibility for its future development, manufacturing, and commercialisation.

The partnership underscores Biogen’s growing focus on immunology and rare diseases as it diversifies beyond its multiple sclerosis portfolio, where revenues have been declining amid rising competition.

Last year, Biogen announced a separate deal worth up to USD 1.8 billion to acquire Human Immunology Biosciences, another company developing treatments for immune-mediated conditions.

Biogen aims to file an application with the U.S. Food and Drug Administration to begin human clinical trials by 2027.